References
- Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018; 8(2): 15-25.
- Vannucchi AM, Harrison CN. Emerging treatment for classical myeloproliferative neoplasms. Blood. 2017; 129(6): 693-703.
- Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352(17): 1779-1790.
- Singdong R, Siriboonpiputtana T, Chareonsiri-suthigul T, Kongruang A, Limsuwanachot N, Sirirat T, et al. Characterisation and prognosis significance of JAK2 (V617F), MPL and CALR mutations in Philadelphia negative myeloproliferative neoplasms. Asian Pac J Cancer Prev. 2016; 17(10): 4647-4653.
- Alshemmari SH, Rajaan R, Ameen R, Al-Drees MA, Almosailleakh MR. JAK2V617F allele burden in patients with myeloproliferative neoplasms. Ann Hematol. 2014; 93(5): 791-796.
- Perricone M, Polverelli N, Martinelli G, Catani L, Ottaviani E, Zuffa E, et al. The relevance of a low JAK2 V617F allele burden in clinical practice: A monocentric study. Oncotarget. 2017; 8(23): 37239-37249.
- Ha, JS, Kim YK, Jung SI, Jung HR, Chung, IS. Correlations between Janus Kinase 2V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms. Ann Lab Med. 2012; 32(6): 385-391.
- Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, et al. Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: A joint European LeukemiaNet MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia. 2013; 27(10): 2032-2039.
- Malysz J, Crisan D. Correlation of JAK2 V617F mutant allele quantification with clinical presentation and type of chronic myeloproliferative neoplasm. Ann Clin Lab Sci. 2009; 39(4): 345-350.
- Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica. 2008; 93(1): 41-48.
- Silver RT, Vandris K, Wang YL, Adriano F, Jones AV, Christos PJ, et al. JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leukemia Res. 2011; 35(2): 177-182.